Will International Pursuit of the Millenium Development Goals Alleviate Poverty in Mountains?

Since September 2000, when world leaders agreed on time-bound, measurable goals to reduce extreme poverty, hunger, illiteracy, and disease while fostering gender equality and ensuring environmental sustainability, the Millennium Development Goals (MDGs) have increasingly come to dominate the policy objectives of many states and development agencies. The concern has been raised that the tight timeframe and financial restrictions might force governments to invest in the more productive sectors, thus compromising the quality and sustainability of development efforts. In the long term, this may lead to even greater inequality, especially between geographical regions and social strata. Hence people living in marginal areas, for example in remote mountain regions, and minority peoples risk being disadvantaged by this internationally agreed agenda. Strategies to overcome hunger and poverty in their different dimensions in mountain areas need to focus on strengthening the economy of small-scale farmers, while also fostering the sustainable use of natural resources, taking into consideration their multifunctionality.

[Will type I diabetes mellitus be treated with immunosuppressive drugs in the future?]

Even if the pathogenesis of type-I (insulin-dependent) diabetes mellitus is still not clarified in every detail, there is general agreement that this form of diabetes is induced by autoimmune mechanisms leading to beta-cell destruction. Therefore, it should theoretically be feasible to suppress the mechanism leading to type-I diabetes with appropriate and early immunotherapy. The current clinical data clearly document that the rate and duration of remissions in patients with newly diagnosed type-I diabetes can be increased significantly using appropriate immunosuppressive regimens. However, before these therapies can become standard therapy of type-I diabetes, the following important clinical requirements have to be fulfilled: the toxicity (especially to kidneys and beta-cells) has to be reduced, the patients should be diagnosed and treated in 'pre-diabetic' states, more selective immunosuppressive regimens have to be available in order to reduce the occurrence of treatment-associated lymphomas and neoplasias. Since accurate detection of 'pre-diabetic' patients is difficult and presents an immense logistic problem, it may take a long time before large-scale immunosuppressive therapies of type-I diabetes are feasible.